IL2RB, IL2RG: IL-2R beta/gamma
Complex in Homo sapiens that 2 drugs act on.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on IL2RB, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 2
| Pegenzileukin | Phase 2 | Sanofi | Protein or peptide | AgonistIL-2R beta/gamma agonist | 1 |
| Simlukafusp alfa | Phase 2 | Roche | Protein or peptide | Binding agentIL-2R beta/gamma binding agent | 1 |
| Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | Pegenzileukin | Phase 1 / Phase 2 | Recruiting | Sanofi | Nov 24, 2020 |
| A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | Simlukafusp alfa | Phase 3 | Active, not recruiting | Hoffmann-La Roche | Dec 7, 2018 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4665588, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets